Mulai
ProfxCapital

SELLAS Announces Pricing of $15 Million Public Offering.

Pembelian
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)  
ProfxCapital  
NASDAQ:SLS   SELLAS Life Sciences Group, Inc.
Beyond Technical Analysis stocksignals stockstrading stockstobuy stocksonthemove pennystocks pennybreakout publicoffering stockstowatch
3
0
beyondta stocksignals stockstrading stockstobuy stocksonthemove pennystocks pennybreakout publicoffering stockstowatch
SELLAS intends to use the net proceeds from the offering to commence a pivotal Phase 3 trial for its lead clinical candidate, galinpepimut-S (“GPS”), as a monotherapy in acute myeloid leukemia patients following second complete remission and to continue its Phase 1/2 basket type trial of GPS in combination with pembrolizumab, as well as for general corporate purposes and funding its working capital needs.
Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.